Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema
Most DME eyes previously responding or not responding to aflibercept experienced a reduction or stabilization of DME after 12 weeks of faricimab treatment. rDME showed a better anatomic response, and treatment intervals could be extended earlier and longer than nrDME.
Authors
- Andreas Pollreisz (ORCID: https://orcid.org/0000-0003-3902-239X)
- Bianca S. Gerendas (ORCID: https://orcid.org/0000-0001-8940-8130)
- Kim Lien Huber (ORCID: https://orcid.org/0000-0001-6075-7580)
- Philipp Fuchs (ORCID: https://orcid.org/0000-0002-9966-6093)
- Heiko Stino
- Katharina Kriechbaum
- Julia Mai (ORCID: https://orcid.org/0000-0002-0528-9742)
- Irene Steiner (ORCID: https://orcid.org/0000-0002-7768-0417)
- Felix Goldbach
- Ursula Schmidt-Erfurth
Institutions
- Medical University of Vienna (AT)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1167/iovs.65.14.46
- Citations
- 13
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.00
Funders
- Apellis Pharmaceuticals
- Genentech
- Allergan